Cargando…

The role and significance of VEGFR2(+) regulatory T cells in tumor immunity

Tumor development is closely related to angiogenesis, and VEGFR2 plays an important role in tumor angiogenesis. It is broadly expressed in the blood vessels, especially in the microvessels of tumor tissues. Furthermore, VEGFR2 is detected on the surface of the cell membrane in various immune cells,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Panrong, Hu, Chenxi, Hui, Kaiyuan, Jiang, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590762/ https://www.ncbi.nlm.nih.gov/pubmed/28919780 http://dx.doi.org/10.2147/OTT.S142085

Ejemplares similares

Effects of combined inhibition of STAT3 and VEGFR2 pathways on the radiosensitivity of non-small-cell lung cancer cells
por: Hu, Chenxi, et al.
Publicado: (2019)

Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
por: Liang, Lijun, et al.
Publicado: (2017)

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
por: Liang, Lijun, et al.
Publicado: (2019)

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
por: Zhang, Yuqing, et al.
Publicado: (2021)

Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
por: Gu, Guoqing, et al.
Publicado: (2021)

NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib
por: Gu, Guoqing, et al.
Publicado: (2021)

Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
por: Xu, Wen Wen, et al.
Publicado: (2014)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
por: Tada, Yasuko, et al.
Publicado: (2018)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy
por: Chen, Jui-Chieh, et al.
Publicado: (2012)

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Prognostic Roles of Cross-Talk between Peritumoral Hepatocytes and Stromal Cells in Hepatocellular Carcinoma Involving Peritumoral VEGF-C, VEGFR-1 and VEGFR-3
por: Zhuang, Peng-Yuan, et al.
Publicado: (2013)

Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

TBX1 Represses Vegfr2 Gene Expression and Enhances the Cardiac Fate of VEGFR2+ Cells
por: Lania, Gabriella, et al.
Publicado: (2015)

Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
por: Li, Yu-Ling, et al.
Publicado: (2016)

Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer
por: N. Abdalla, Ashraf, et al.
Publicado: (2020)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation
por: Mu, Xianmin, et al.
Publicado: (2012)

The regulatory mechanism and biological significance of the Snail-miR590-VEGFR-NRP1 axis in the angiogenesis, growth and metastasis of gastric cancer
por: Mei, Bin, et al.
Publicado: (2020)

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
por: Kratzsch, Tobias, et al.
Publicado: (2020)

Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(−)CD45(+) cells during hepatocellular carcinoma progression
por: Zhu, Xiaolin, et al.
Publicado: (2017)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

The Immune Regulatory Role of Adenosine in the Tumor Microenvironment
por: Xing, Jianlei, et al.
Publicado: (2023)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer
por: Shi, Xiaoyan, et al.
Publicado: (2008)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression
por: Chung, Tae-Wook, et al.
Publicado: (2017)

VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment
por: Jaal, Jana, et al.
Publicado: (2015)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer
por: D’Haene, Nicky, et al.
Publicado: (2018)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

Circulating CD133(+)VEGFR2(+) and CD34(+)VEGFR2(+) cells and arterial function in patients with beta-thalassaemia major
por: Cheung, Yiu-fai, et al.
Publicado: (2011)

Blockade of VEGFR2 and Not VEGFR1 Can Limit Diet-Induced Fat Tissue Expansion: Role of Local versus Bone Marrow-Derived Endothelial Cells
por: Tam, Joshua, et al.
Publicado: (2009)

VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis
por: Virtej, Anca, et al.
Publicado: (2016)

Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer
por: Yang, Ju, et al.
Publicado: (2019)

Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
por: Wang, Xinrong, et al.
Publicado: (2020)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Integrin β(3) Crosstalk with VEGFR Accommodating Tyrosine Phosphorylation as a Regulatory Switch
por: West, Xiaoxia Z., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ao9t0ih8u4stutagv935kshpi8